10-Q: Picard Medical Reports Q2 2026 Results, Faces Going Concern Warning

Picard Medical, Inc. (PMI) filed its Q2 2026 Form 10-Q, revealing revenue growth but also substantial operating losses, a significant decrease in cash, and a going concern warning from management.

Summary

• Picard Medical, Inc. reported its Q2 2026 results, showing total revenues of $4.1 million for the six months ended June 30, 2026, a 50% increase from $2.7 million in the prior year period.
• Despite revenue growth, the company incurred a net loss of $13.3 million for the six months ended June 30, 2026, compared to a net loss of $12.3 million in the same period last year.
• Total assets decreased to $9.2 million as of June 30, 2026, from $22.5 million as of December 31, 2025, largely due to a significant reduction in cash and cash equivalents and warrant liability.
• The company has substantial debt obligations, including a Senior Secured Note that has been significantly reduced through settlements and repayments.
• Management has expressed substantial doubt about the company's ability to continue as a going concern, citing ongoing operating losses and the need for additional financing.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to significant ongoing losses, substantial debt, and a going concern warning, despite some revenue growth.

Positives

• Total revenues increased by 50% to $4.1 million for the six months ended June 30, 2026, compared to $2.7 million for the same period in 2025.
• Product revenues increased by 41% to $3.9 million for the six months ended June 30, 2026, compared to $2.7 million in the prior year.
• Rental revenues were $226,000 for the six months ended June 30, 2026, compared to no rental revenue in the prior year period.
• Gross profit improved significantly to $891,000 for the six months ended June 30, 2026, from a loss of $485,000 in the prior year period, indicating better cost management on product sales.
• The company received acceptance from NYSE American for its plan to regain compliance with continued listing standards.

Negatives

• The company incurred a net loss of $13.3 million for the six months ended June 30, 2026, an increase from $12.3 million in the prior year period.
• Operating expenses increased by 60% to $10.0 million for the six months ended June 30, 2026, from $6.3 million in the prior year period.
• Cash and cash equivalents decreased significantly to $38,000 as of June 30, 2026, from $7.5 million as of December 31, 2025.
• The company has a substantial accumulated deficit of $90.1 million as of June 30, 2026.
• The company's independent registered public accounting firm included an explanatory paragraph relating to its ability to continue as a going concern in its report on its audited financial statements.

Risks

• Loss of, reduced purchases by, or delayed payments from customers, who are concentrated among a limited number of heart transplant centers, hospitals, surgeons, and their distributors.
• Reliance on a limited number of products, with potential material impact from any disruption in production, quality, regulatory status, safety, or market acceptance.
• Complex, highly manual, and concentrated manufacturing processes expose the company to risks related to workforce constraints, training timelines, equipment failures, and regulatory noncompliance.
• Reliance on single- or limited-source suppliers for critical components, increasing the risk of shortages.
• Delays or failure to obtain certification under EU Medical Devices Regulation could limit growth in European markets.
• Clinical studies are costly, lengthy, and uncertain, with potential for delays or failure to obtain approvals.
• Device malfunctions or quality issues could lead to field actions, recalls, investigations, and reputational harm.
• The company faces significant penalties, sanctions, and litigation exposure if its products are misused.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future, requiring additional equity and debt financing to fund operations until positive cash flows are generated. Development of the next-generation Emperor Total Artificial Heart is ongoing, with a long-term objective of building the world's first fully implantable total artificial heart.

Management Comments

• "To the extent that we raise additional capital through the future sale of equity or debt, the ownership interest of our stockholders will be diluted."
• "If we are unable to raise sufficient funds through equity or debt financing, we may be required to delay, limit, curtail or terminate our product development or future growth efforts."
• "We have considered that our long-term operations anticipate continuing net losses and the need for potential debt or equity financing."
• "There can be no assurances that additional funding or other sources of capital will be available on terms acceptable to us, or at all."
• "As a result of these conditions, we have concluded that there is substantial doubt over our ability to continue as a going concern as conditions and events, considered in the aggregate, indicate it is probable we will be unable to meet our obligations as they become due within one year after the date that the financial statements included in this filing are issued."

Industry Context

StockSavvy.ai notes that Picard Medical operates in the highly competitive and regulated medical device sector, specifically focusing on advanced cardiac support solutions. The development of a fully implantable total artificial heart (Emperor TAH) positions the company for potential future innovation, but faces significant R&D and regulatory hurdles, common in this industry.

Comparison to Industry Standards

• Companies in the advanced medical device sector, particularly those developing implantable devices, typically require substantial long-term investment in R&D and regulatory approvals, often leading to extended periods of unprofitability.
• The development timeline for novel medical technologies like a fully implantable total artificial heart can span many years and involve significant capital expenditure, similar to other complex medical device innovations.
• The regulatory pathway for such devices, involving FDA and international bodies, is rigorous and costly, a standard challenge faced by all companies in this space.
• The need for ongoing capital raises is a common characteristic of early-stage medical technology companies, as they navigate development, clinical trials, and market entry.

Corporate Governance

Legal Proceedings

• A putative securities class action lawsuit (Louie v. Picard Medical, Inc., et al.) was filed in February 2026, alleging claims under Sections 11 and 15 of the Securities Act of 1933 concerning material omissions in the IPO registration statement regarding market structure or stock price manipulation risks. The company believes the claims are without merit and intends to defend vigorously.

Related Party Transactions

• Loans from Fang Family Fund II, LLC and Fang Family Fund I, LLC, affiliated with an executive director and Interim Chief Executive Officer, totaling $1.75 million in 2025 and $0.7 million in February 2026. These loans bear 6% interest.
• Stock options granted to Chris Hsieh, a consultant, in May 2026.

Stakeholder Impact

• Shareholders face potential dilution from future equity financings and continued uncertainty regarding profitability and stock price volatility.
• Creditors and noteholders face risks associated with the company's ability to meet its debt obligations, although recent debt settlements and repayments have reduced some of these liabilities.
• Employees may face uncertainty due to the going concern warning and the company's need to scale operations.
• The company's ability to continue listing on the NYSE American is subject to regaining compliance, impacting market access and liquidity for all stakeholders.

Next Steps

• Continue development of the Emperor TAH program.
• Regain compliance with NYSE American continued listing standards within the 18-month period ending November 8, 2027.
• Seek additional debt and/or equity financing to fund operations.
• Transition to a majority independent board by May 6, 2027.

Key Dates

Recommendation

The company exhibits significant financial distress, characterized by increasing net losses, a drastic reduction in cash reserves, substantial debt, and a formal going concern warning from management. While there is revenue growth, it is insufficient to offset the high operating expenses and R&D investments. The ongoing litigation and the need for continuous capital raises further increase risk. Until the company demonstrates a clear path to profitability and resolves its liquidity concerns, a sell recommendation is warranted.

Keywords

Total Artificial Heart, SynCardia TAH, Medical Device, Heart Failure, Emperor TAH, FDA Approval, Medical Technology, Cardiac Support